Previous 10 | Next 10 |
Key Highlights: First Quarter of FY2020 (Q1) North American sales grew by 111% YoY to $269K AUD Q1 US Travelan® sales increased by +81% YoY to $232K AUD Global Immuron sales continued an upward trend in Q1 with a +54% YoY sales increase, reaching $741K AUD In Australi...
Immuron ( IMRN +22.4% ) announces the funding of a new research agreement with the Naval Medical Research Center (NMRC), Silver Spring, MD, USA. More news on: Immuron Limited, Healthcare stocks news, Stocks on the move, Read more ...
Immuron (NASDAQ: IMRN ) +34% on new research agreement with the Naval Medical Research Center. More news on: Immuron Limited, The Stars Group Inc., Axsome Therapeutics, Inc., Stocks on the move, Read more ...
Key Highlights: AU $5.5 (USD $3.7) million funding approved by the U.S. Department of Defense to develop and clinically evaluate a new oral therapeutic targeting Campylobacter and ETEC Naval Medical Research Center will fund the manufacture and therapeutic evaluation of the new ...
Key Highlights: Major goal of study was to evaluate Travelan®’s ability to bind and react to a variety of infectious Vibrio cholera strains from Southeast Asia Pathogenic bacteria evaluated in study were obtained from infected personnel deployed in Banglades...
MELBOURNE, Australia, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today is pleased to release to sha...
MELBOURNE, Australia, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced the topline results of the ...
Gainers: Nautilus (NYSE: NLS ) +21% . Francesca's Holdings (NASDAQ: FRAN ) +20% . Anixa Biosciences (NASDAQ: ANIX ) +19% . AVROBIO (NASDAQ: AVRO ) +19% . Rekor Systems (REKR) +18% . Seattle Genetics (NASDAQ: SGEN ) +18% . Hill International (NYSE: HIL ) +18% . scPharmaceutical...
Immuron (NASDAQ: IMRN ) has priced its public offering of 339,130 ADSs, at $4.00 per share, for gross proceeds of ~$1,356,520. Each ADS represents 40 ordinary shares of the Company. More news on: Immuron Limited, Healthcare stocks news, Stocks on the move, Read more ...
Xenetic Biosciences (NASDAQ: XBIO ) -47% on pricing $15M public offering. More news on: Xenetic Biosciences, Inc., Nu Skin Enterprises, Inc., Immuron Limited, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Sales Highlights: MELBOURNE, Australia, July 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce record sales (unaudited) of Travelan ® , an over-the-counter immune ...
MELBOURNE, Australia, July 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce that it has filed a pre-IND (investigational new drug) application with the United States Food and Drug A...
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has resigned from his position as Non-Executive Director effective today. Roger was appointed a...